Page last updated: 2024-10-17

bupropion and Weight Loss

bupropion has been researched along with Weight Loss in 62 studies

Bupropion: A propiophenone-derived antidepressant and antismoking agent that inhibits the uptake of DOPAMINE.
bupropion : An aromatic ketone that is propiophenone carrying a tert-butylamino group at position 2 and a chloro substituent at position 3 on the phenyl ring.

Weight Loss: Decrease in existing BODY WEIGHT.

Research Excerpts

ExcerptRelevanceReference
" The authors tested the effectiveness of naltrexone-bupropion and behavioral weight loss therapy (BWL), alone and combined, for binge-eating disorder comorbid with obesity."9.51Naltrexone-Bupropion and Behavior Therapy, Alone and Combined, for Binge-Eating Disorder: Randomized Double-Blind Placebo-Controlled Trial. ( Fineberg, SK; Grilo, CM; Gueorguieva, R; Ivezaj, V; Lydecker, JA; Moreno, JO, 2022)
" The new combination of naltrexone and bupropion sustained release (NB) has proved to be effective for weight loss among obese patients."9.41An open-label trial on the efficacy and tolerability of naltrexone/bupropion SR for treating altered eating behaviours and weight loss in binge eating disorder. ( Aloi, M; Arturi, F; Calabrò, G; Carbone, EA; Caroleo, M; Condoleo, F; de Filippis, R; Rania, M; Segura-Garcia, C; Staltari, FA, 2021)
"This study assessed the effects of 32 mg naltrexone sustained release (SR)/360 mg bupropion SR (NB) on body weight in adults with obesity, with comprehensive lifestyle intervention (CLI), for 78 weeks."9.24Method-of-use study of naltrexone sustained release (SR)/bupropion SR on body weight in individuals with obesity. ( Fujioka, K; Gilder, K; Halseth, A; Shan, K; Walsh, B, 2017)
"To examine the effects of naltrexone/bupropion (NB) combination therapy on weight and weight-related risk factors in overweight and obese participants."9.17A randomized, phase 3 trial of naltrexone SR/bupropion SR on weight and obesity-related risk factors (COR-II). ( Apovian, CM; Aronne, L; Burns, C; Dunayevich, E; Kim, D; Rubino, D; Still, C; Wyatt, H, 2013)
"Bupropion was well tolerated and produced significantly greater-albeit quite modest-short-term weight loss in overweight and obese women with BED."9.17Bupropion for overweight women with binge-eating disorder: a randomized, double-blind, placebo-controlled trial. ( Grilo, CM; White, MA, 2013)
"To assess the efficacy and safety of 32 mg naltrexone sustained-release (SR)/360 mg bupropion SR (NB) in overweight/obese individuals with type 2 diabetes with or without background oral antidiabetes drugs."9.17Effects of naltrexone sustained-release/bupropion sustained-release combination therapy on body weight and glycemic parameters in overweight and obese patients with type 2 diabetes. ( Bays, H; Burns, C; Fujioka, K; Greenway, F; Gupta, AK; Hollander, P; Klassen, P; Plodkowski, R, 2013)
"A sustained-release combination of naltrexone plus bupropion could be a useful therapeutic option for treatment of obesity."9.14Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. ( Dunayevich, E; Erickson, J; Fujioka, K; Greenway, FL; Guttadauria, M; Kim, DD; Mudaliar, S; Plodkowski, RA, 2010)
"Our objective was to determine whether opioid receptor antagonism (naltrexone) plus pro-opiomelanocortin activation (bupropion) causes greater weight loss than placebo or monotherapy."9.14Comparison of combined bupropion and naltrexone therapy for obesity with monotherapy and placebo. ( Cowley, MA; Dunayevich, E; Erickson, J; Fujioka, K; Greenway, FL; Guttadauria, M; Tollefson, G, 2009)
"In this short-term, open-label, preliminary trial, combination treatment of zonisamide and bupropion resulted in more weight loss than treatment with zonisamide alone."9.12Combination therapy of zonisamide and bupropion for weight reduction in obese women: a preliminary, randomized, open-label study. ( Foust, MS; Gadde, KM; Wagner, HR; Yonish, GM, 2007)
"To examine the effectiveness of bupropion in reducing bodyweight gained during treatment with olanzapine."9.12Bupropion treatment of olanzapine-associated weight gain: an open-label, prospective trial. ( Foust, MS; Gadde, KM; Zhang, W, 2006)
"Bupropion SR in combination with a 500 kcal/d-deficit diet facilitated weight loss."9.10Bupropion SR vs. placebo for weight loss in obese patients with depressive symptoms. ( Allison, DB; Brewer, ER; Buaron, KS; Gadde, KM; Haight, B; Jain, AK; Jamerson, BD; Kaplan, RA; Leadbetter, RA; Metz, A; Richard, N; Wadden, TA, 2002)
"To critically examine the efficacy of bupropion SR for weight loss."9.10Bupropion SR enhances weight loss: a 48-week double-blind, placebo- controlled trial. ( Anderson, JW; Fujioka, K; Gadde, KM; Greenway, FL; McKenney, J; O'Neil, PM, 2002)
"Subjects receiving bupropion achieved greater mean weight loss (last-observation-carried-forward analysis) over the first 8 weeks of the study (p = 0."9.09Bupropion for weight loss: an investigation of efficacy and tolerability in overweight and obese women. ( Drezner, MK; Gadde, KM; Krishnan, KR; Logue, EJ; Maner, LG; Parker, CB; Wagner, HR, 2001)
"Contrave(®) is a combination of naltrexone hydrochloride extended release and bupropion hydrochloride extended release for the treatment of obesity, and is used with lifestyle modification."8.93Naltrexone/bupropion for the treatment of obesity and obesity with Type 2 diabetes. ( Apovian, CM, 2016)
"The mechanism of action of the combination therapy, naltrexone/bupropion (NB), for obesity has not been fully described to date."8.90Naltrexone/bupropion for obesity: an investigational combination pharmacotherapy for weight loss. ( Billes, SK; Cowley, MA; Sinnayah, P, 2014)
"This review examines the safety and antiobesity effects of naltrexone and bupropion alone and in combination."8.90Drug safety evaluation of naltrexone/bupropion for the treatment of obesity. ( Bello, NT; Verpeut, JL, 2014)
"Naltrexone/bupropion is an investigational combination for weight loss and maintenance in patients who are obese or have a BMI ≥ 27 kg/m(2) with comorbid diabetes, hypertension or hyperlipidemia."8.87Naltrexone/bupropion: an investigational combination for weight loss and maintenance. ( Gwinn, KM; Hurren, KM; Makowski, CT, 2011)
" Appropriate patient management should address the mild sympathomimetic effect of bupropion, although the FDA has required that a cardiovascular outcomes study be conducted preapproval to determine the effects of long-term use of naltrexone/bupropion in an overweight/obese population."8.87Combination therapy with naltrexone and bupropion for obesity. ( Billes, SK; Greenway, FL, 2011)
" While the opioid receptor antagonist naltrexone is associated with minimal weight loss as monotherapy, it does have potential utility in the treatment of obesity when combined with the pro-opiomelanocortin activator bupropion."8.85Naltrexone for the treatment of obesity: review and update. ( Fujioka, K; Lee, MW, 2009)
"Both bupropion and naltrexone have been shown individually to induce weight loss."8.85Bupropion and naltrexone: a review of their use individually and in combination for the treatment of obesity. ( Chau, DL; Nguyen, L; Nguyen, Q; Plodkowski, RA; St Jeor, S; Sundaram, U, 2009)
"Contrave, under development by Orexigen Therapeutics Inc for the potential treatment of obesity, is an oral, sustained-release combination of the dopamine and norepinephrine reuptake antagonist bupropion and the opioid antagonist naltrexone."8.85Contrave, a bupropion and naltrexone combination therapy for the potential treatment of obesity. ( Padwal, R, 2009)
"To investigate the changes of circulating levels of all proglucagon-derived peptides (PGDPs) in individuals with overweight or obesity receiving liraglutide (3 mg) or naltrexone/bupropion (32/360 mg), and to explore the association between induced changes in postprandial PGDP levels and body composition, as well as metabolic variables, after 3 and 6 months on treatment."8.31Circulating levels of proglucagon-derived peptides are differentially regulated by the glucagon-like peptide-1 agonist liraglutide and the centrally acting naltrexone/bupropion and can predict future weight loss and metabolic improvements: A 6-month long ( Argyrakopoulou, G; Bontozoglou, N; Kalra, B; Kokkinos, A; Konstantinidou, SK; Kouvari, M; Kumar, A; Kumar, M; Kyriakopoulou, K; Mantzoros, CS; Simati, S; Stefanakis, K, 2023)
"Weight loss is associated with improved quality of life in some, but not all, weight loss trials."6.80Patient-reported quality of life in a randomized placebo-controlled trial of naltrexone/bupropion for obesity. ( Chen, S; Gilder, K; Greenway, FL; Klassen, P; Kolotkin, RL, 2015)
"The prevalence of obesity is growing rapidly worldwide, and therefore there is a need for effective treatment strategies."6.47Naltrexone sustained-release (SR) + bupropion SR combination therapy for the treatment of obesity: 'a new kid on the block'? ( Hatzitolios, AI; Katsiki, N; Mikhailidis, DP, 2011)
"Bupropion is a norepinephrine and dopamine uptake inhibitor that has been available for several years for the treatment of depression and aiding smokers to quit."6.44Bupropion for weight reduction. ( Gadde, KM; Xiong, GL, 2007)
" The authors tested the effectiveness of naltrexone-bupropion and behavioral weight loss therapy (BWL), alone and combined, for binge-eating disorder comorbid with obesity."5.51Naltrexone-Bupropion and Behavior Therapy, Alone and Combined, for Binge-Eating Disorder: Randomized Double-Blind Placebo-Controlled Trial. ( Fineberg, SK; Grilo, CM; Gueorguieva, R; Ivezaj, V; Lydecker, JA; Moreno, JO, 2022)
" The new combination of naltrexone and bupropion sustained release (NB) has proved to be effective for weight loss among obese patients."5.41An open-label trial on the efficacy and tolerability of naltrexone/bupropion SR for treating altered eating behaviours and weight loss in binge eating disorder. ( Aloi, M; Arturi, F; Calabrò, G; Carbone, EA; Caroleo, M; Condoleo, F; de Filippis, R; Rania, M; Segura-Garcia, C; Staltari, FA, 2021)
"This study assessed the effects of 32 mg naltrexone sustained release (SR)/360 mg bupropion SR (NB) on body weight in adults with obesity, with comprehensive lifestyle intervention (CLI), for 78 weeks."5.24Method-of-use study of naltrexone sustained release (SR)/bupropion SR on body weight in individuals with obesity. ( Fujioka, K; Gilder, K; Halseth, A; Shan, K; Walsh, B, 2017)
"Bupropion was well tolerated and produced significantly greater-albeit quite modest-short-term weight loss in overweight and obese women with BED."5.17Bupropion for overweight women with binge-eating disorder: a randomized, double-blind, placebo-controlled trial. ( Grilo, CM; White, MA, 2013)
"To assess the efficacy and safety of 32 mg naltrexone sustained-release (SR)/360 mg bupropion SR (NB) in overweight/obese individuals with type 2 diabetes with or without background oral antidiabetes drugs."5.17Effects of naltrexone sustained-release/bupropion sustained-release combination therapy on body weight and glycemic parameters in overweight and obese patients with type 2 diabetes. ( Bays, H; Burns, C; Fujioka, K; Greenway, F; Gupta, AK; Hollander, P; Klassen, P; Plodkowski, R, 2013)
"To examine the effects of naltrexone/bupropion (NB) combination therapy on weight and weight-related risk factors in overweight and obese participants."5.17A randomized, phase 3 trial of naltrexone SR/bupropion SR on weight and obesity-related risk factors (COR-II). ( Apovian, CM; Aronne, L; Burns, C; Dunayevich, E; Kim, D; Rubino, D; Still, C; Wyatt, H, 2013)
" Here, we explore combination therapy with bupropion (BUP), a putative stimulator of melanocortin pathways, and an opioid antagonist, naltrexone (NAL), to antagonize an inhibitory feedback loop that limits sustained weight reduction."5.14Rational design of a combination medication for the treatment of obesity. ( Anderson, JW; Atkinson, RL; Cowley, MA; Dunayevich, E; Fujioka, K; Gadde, KM; Greenway, FL; Gupta, AK; Guttadauria, M; O'Neil, P; Schumacher, D; Smith, D; Tollefson, GD; Weber, E; Whitehouse, MJ, 2009)
"Our objective was to determine whether opioid receptor antagonism (naltrexone) plus pro-opiomelanocortin activation (bupropion) causes greater weight loss than placebo or monotherapy."5.14Comparison of combined bupropion and naltrexone therapy for obesity with monotherapy and placebo. ( Cowley, MA; Dunayevich, E; Erickson, J; Fujioka, K; Greenway, FL; Guttadauria, M; Tollefson, G, 2009)
"A sustained-release combination of naltrexone plus bupropion could be a useful therapeutic option for treatment of obesity."5.14Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. ( Dunayevich, E; Erickson, J; Fujioka, K; Greenway, FL; Guttadauria, M; Kim, DD; Mudaliar, S; Plodkowski, RA, 2010)
"To examine the effectiveness of bupropion in reducing bodyweight gained during treatment with olanzapine."5.12Bupropion treatment of olanzapine-associated weight gain: an open-label, prospective trial. ( Foust, MS; Gadde, KM; Zhang, W, 2006)
"In this short-term, open-label, preliminary trial, combination treatment of zonisamide and bupropion resulted in more weight loss than treatment with zonisamide alone."5.12Combination therapy of zonisamide and bupropion for weight reduction in obese women: a preliminary, randomized, open-label study. ( Foust, MS; Gadde, KM; Wagner, HR; Yonish, GM, 2007)
"Bupropion SR in combination with a 500 kcal/d-deficit diet facilitated weight loss."5.10Bupropion SR vs. placebo for weight loss in obese patients with depressive symptoms. ( Allison, DB; Brewer, ER; Buaron, KS; Gadde, KM; Haight, B; Jain, AK; Jamerson, BD; Kaplan, RA; Leadbetter, RA; Metz, A; Richard, N; Wadden, TA, 2002)
"To critically examine the efficacy of bupropion SR for weight loss."5.10Bupropion SR enhances weight loss: a 48-week double-blind, placebo- controlled trial. ( Anderson, JW; Fujioka, K; Gadde, KM; Greenway, FL; McKenney, J; O'Neil, PM, 2002)
"Subjects receiving bupropion achieved greater mean weight loss (last-observation-carried-forward analysis) over the first 8 weeks of the study (p = 0."5.09Bupropion for weight loss: an investigation of efficacy and tolerability in overweight and obese women. ( Drezner, MK; Gadde, KM; Krishnan, KR; Logue, EJ; Maner, LG; Parker, CB; Wagner, HR, 2001)
"Four new medicines-liraglutide, lorcaserin, bupropion/naltrexone, and phentermine/topiramate-have been recently added to the pharmacological arsenal for obesity treatment and could represent important tools to manage this epidemic disease."5.01Gender-related issues in the pharmacology of new anti-obesity drugs. ( Barrea, L; Cataldi, M; Colao, A; Guida, B; Muscogiuri, G; Savastano, S; Taglialatela, M, 2019)
" The aim of the present review is to summarize the current data on the eff ects of antiobesity drugs approved in Europe (orlistat, liraglutide 3 mg od and naltrexone/bupropion) on weight loss in patients with PCOS and to discuss their impact on the endocrine, reproductive and metabolic abnormalities of this population."4.98The Role of Antiobesity Agents in the Management of Polycystic Ovary Syndrome. ( Chatzis, P; Dinas, K; Makris, V; Pratilas, GC; Sotiriadis, A; Tziomalos, K, 2018)
" Phentermine/topiramate ER appeared to have the best overall average weight loss from baseline as well as highest percentages of patients achieving both ≥5% and ≥10% weight loss benchmarks, followed second by naltrexone/bupropion, and then liraglutide, with lorcaserin showing the lowest rates."4.93A Comparison of New Pharmacological Agents for the Treatment of Obesity. ( Megyeri, J; Nuffer, W; Trujillo, JM, 2016)
"Contrave(®) is a combination of naltrexone hydrochloride extended release and bupropion hydrochloride extended release for the treatment of obesity, and is used with lifestyle modification."4.93Naltrexone/bupropion for the treatment of obesity and obesity with Type 2 diabetes. ( Apovian, CM, 2016)
"The mechanism of action of the combination therapy, naltrexone/bupropion (NB), for obesity has not been fully described to date."4.90Naltrexone/bupropion for obesity: an investigational combination pharmacotherapy for weight loss. ( Billes, SK; Cowley, MA; Sinnayah, P, 2014)
"This review examines the safety and antiobesity effects of naltrexone and bupropion alone and in combination."4.90Drug safety evaluation of naltrexone/bupropion for the treatment of obesity. ( Bello, NT; Verpeut, JL, 2014)
"A short overview of new drugs approved for the treatment of obesity (lorcaserin, phentermine/topiramate combination) as well as those with a perspective for approval as antiobesity drugs (cetilistat, naltrexone/bupropion combination, liraglutide) is presented."4.90Overview of new antiobesity drugs. ( Hainer, V, 2014)
"Naltrexone/bupropion is an investigational combination for weight loss and maintenance in patients who are obese or have a BMI ≥ 27 kg/m(2) with comorbid diabetes, hypertension or hyperlipidemia."4.87Naltrexone/bupropion: an investigational combination for weight loss and maintenance. ( Gwinn, KM; Hurren, KM; Makowski, CT, 2011)
"Contrave is an investigational fixed-dose combination drug of naltrexone and bupropion currently in Phase III clinical trials for the treatment of obesity."4.87ACS chemical neuroscience molecule spotlight on contrave. ( Mercer, SL, 2011)
" Appropriate patient management should address the mild sympathomimetic effect of bupropion, although the FDA has required that a cardiovascular outcomes study be conducted preapproval to determine the effects of long-term use of naltrexone/bupropion in an overweight/obese population."4.87Combination therapy with naltrexone and bupropion for obesity. ( Billes, SK; Greenway, FL, 2011)
"Both bupropion and naltrexone have been shown individually to induce weight loss."4.85Bupropion and naltrexone: a review of their use individually and in combination for the treatment of obesity. ( Chau, DL; Nguyen, L; Nguyen, Q; Plodkowski, RA; St Jeor, S; Sundaram, U, 2009)
" While the opioid receptor antagonist naltrexone is associated with minimal weight loss as monotherapy, it does have potential utility in the treatment of obesity when combined with the pro-opiomelanocortin activator bupropion."4.85Naltrexone for the treatment of obesity: review and update. ( Fujioka, K; Lee, MW, 2009)
"Contrave, under development by Orexigen Therapeutics Inc for the potential treatment of obesity, is an oral, sustained-release combination of the dopamine and norepinephrine reuptake antagonist bupropion and the opioid antagonist naltrexone."4.85Contrave, a bupropion and naltrexone combination therapy for the potential treatment of obesity. ( Padwal, R, 2009)
"To investigate the changes of circulating levels of all proglucagon-derived peptides (PGDPs) in individuals with overweight or obesity receiving liraglutide (3 mg) or naltrexone/bupropion (32/360 mg), and to explore the association between induced changes in postprandial PGDP levels and body composition, as well as metabolic variables, after 3 and 6 months on treatment."4.31Circulating levels of proglucagon-derived peptides are differentially regulated by the glucagon-like peptide-1 agonist liraglutide and the centrally acting naltrexone/bupropion and can predict future weight loss and metabolic improvements: A 6-month long ( Argyrakopoulou, G; Bontozoglou, N; Kalra, B; Kokkinos, A; Konstantinidou, SK; Kouvari, M; Kumar, A; Kumar, M; Kyriakopoulou, K; Mantzoros, CS; Simati, S; Stefanakis, K, 2023)
" This analysis looked at the add-on of NB to incretins to see if weight loss could occur in patients already stabilized on incretin agents."4.02Extended-release naltrexone/bupropion is safe and effective among subjects with type 2 diabetes already taking incretin agents: a post-hoc analysis of the LIGHT trial. ( Barakat, M; Blavignac, J; Burrows, M; Camacho, F; Christensen, RAG; Gould, E; Kamran, E; Wharton, S; Yin, P, 2021)
"The recent approval of liraglutide, lorcaserin, naltrexone/bupropion extended-release, and phentermine/topiramate extended-release, brings the number of medications for long-term weight loss to 5 (including orlistat)."3.83Answers to Clinical Questions in the Primary Care Management of People with Obesity: Pharmacologic Management. ( Braverman-Panza, J; Fujioka, K, 2016)
" Importantly, the appetite suppressant-induced weight loss and locomotion were markedly reduced by intragastric (and intra-NAc shell) infusions of dopamine antagonists SCH-23390 (D1 receptor) or raclopride (D2 receptor)."3.81D1 and D2 antagonists reverse the effects of appetite suppressants on weight loss, food intake, locomotion, and rebalance spiking inhibition in the rat NAc shell. ( Elias, D; Gutierrez, R; Kalyanasundar, B; Luna, A; Moreno, MG; Perez, CI; Simon, SA; Solorio, J, 2015)
"The significant weight loss observed with combination naltrexone-sustained release (SR) 32 mg and bupropion SR 360 mg (NB32) therapy is thought to be due, in part, to bupropion stimulation of hypothalamic pro-opiomelanocortin (POMC) neurons, and naltrexone blockade of opioid receptor-mediated POMC autoinhibition, but the neurobiological mechanisms are not fully understood."3.80Effect of combined naltrexone and bupropion therapy on the brain's reactivity to food cues. ( Caparelli, EC; Dunayevich, E; Telang, F; Tomasi, D; Volkow, ND; Wang, GJ; Wang, R, 2014)
"Bupropion (BUP) is a dopamine (DA) and norepinephrine (NE) reuptake inhibitor that causes mild weight loss in obese adults."3.74Catecholamine reuptake inhibition causes weight loss by increasing locomotor activity and thermogenesis. ( Billes, SK; Cowley, MA, 2008)
"Weight loss is associated with improved quality of life in some, but not all, weight loss trials."2.80Patient-reported quality of life in a randomized placebo-controlled trial of naltrexone/bupropion for obesity. ( Chen, S; Gilder, K; Greenway, FL; Klassen, P; Kolotkin, RL, 2015)
" The purpose of the study is to determine the relationship between these treatments and the risk of major cardiovascular adverse events (MACE)."2.72Cardiovascular safety of naltrexone and bupropion therapy: Systematic review and meta-analyses. ( Aguilar-Salinas, C; Benchimol, A; Bonilha, I; Carvalho, LSF; Cercato, C; Geloneze, B; Hohl, A; Luchiari, B; Moura, F; Nadruz, W; Sposito, AC, 2021)
" However, they are costly and may have adverse effects in some individuals."2.72Long-Term Efficacy and Safety of Anti-Obesity Treatment: Where Do We Stand? ( Lee, SY; Tak, YJ, 2021)
" Thus, if following the appropriate guidelines according to package labels, the practitioner can feel safe in prescribing these medications."2.52Safety and tolerability of medications approved for chronic weight management. ( Fujioka, K, 2015)
"The prevalence of obesity is rising worldwide, with the U."2.48Recent advancements in drug treatment of obesity. ( Carter, R; Mouralidarane, A; Oben, J; Ray, S; Soeda, J, 2012)
"The prevalence of obesity is growing rapidly worldwide, and therefore there is a need for effective treatment strategies."2.47Naltrexone sustained-release (SR) + bupropion SR combination therapy for the treatment of obesity: 'a new kid on the block'? ( Hatzitolios, AI; Katsiki, N; Mikhailidis, DP, 2011)
"Bupropion is a norepinephrine and dopamine uptake inhibitor that has been available for several years for the treatment of depression and aiding smokers to quit."2.44Bupropion for weight reduction. ( Gadde, KM; Xiong, GL, 2007)
"Mean (SD) weight loss was 5."1.62Weight-loss response to naltrexone/bupropion is modulated by the Taq1A genetic variant near DRD2 (rs1800497): A pilot study. ( Chung, WK; Febres, G; Holleran, S; Korner, J; LeDuc, CA; Mullally, JA; Ramakrishnan, R; Reid, TJ, 2021)
"Maintaining weight loss is extremely difficult due to the neuro-endocrine dysregulations that stimulate the body to return to the previous, increased, weight."1.62[Pharmacotherapy for obesity]. ( Abawi, O; van den Akker, ELT; van der Valk, ES; van der Voorn, B; van Rossum, EFC; Welling, MS, 2021)
"Obesity is a chronic disease universally defined as an excess of adipose tissue resulting in body mass index (BMI) > 30."1.46Obesity Epidemic: Pharmaceutical Weight Loss. ( Curry, SA, 2017)

Research

Studies (62)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's12 (19.35)29.6817
2010's38 (61.29)24.3611
2020's12 (19.35)2.80

Authors

AuthorsStudies
Grilo, CM2
Lydecker, JA1
Fineberg, SK1
Moreno, JO1
Ivezaj, V1
Gueorguieva, R1
BouSaba, J1
Vosoughi, K1
Dilmaghani, S1
Prokop, LJ1
Camilleri, M1
Stefanakis, K1
Kokkinos, A1
Argyrakopoulou, G1
Konstantinidou, SK1
Simati, S1
Kouvari, M1
Kumar, A1
Kalra, B1
Kumar, M1
Bontozoglou, N1
Kyriakopoulou, K1
Mantzoros, CS1
Thomas, B2
Lindblad, AJ2
Luu, T2
Paige, A2
Carbone, EA1
Caroleo, M1
Rania, M1
Calabrò, G1
Staltari, FA1
de Filippis, R1
Aloi, M1
Condoleo, F1
Arturi, F1
Segura-Garcia, C1
Milano, W1
De Biasio, V1
Di Munzio, W1
Foggia, G1
Capasso, A1
Mullally, JA1
Chung, WK1
LeDuc, CA1
Reid, TJ1
Febres, G1
Holleran, S1
Ramakrishnan, R1
Korner, J1
Tak, YJ1
Lee, SY1
van Rossum, EFC1
Welling, MS1
van der Voorn, B1
van der Valk, ES1
Abawi, O1
van den Akker, ELT1
Sposito, AC1
Bonilha, I1
Luchiari, B1
Benchimol, A1
Hohl, A1
Moura, F1
Cercato, C1
Geloneze, B1
Nadruz, W1
Aguilar-Salinas, C1
Carvalho, LSF1
Wharton, S1
Yin, P1
Burrows, M1
Gould, E1
Blavignac, J1
Christensen, RAG1
Kamran, E1
Camacho, F1
Barakat, M1
Dalton, M1
Finlayson, G1
Walsh, B3
Halseth, AE2
Duarte, C1
Blundell, JE1
Wilding, JPH1
Cataldi, M1
Muscogiuri, G1
Savastano, S1
Barrea, L1
Guida, B1
Taglialatela, M1
Colao, A1
Chatzis, P1
Tziomalos, K1
Pratilas, GC1
Makris, V1
Sotiriadis, A1
Dinas, K1
Apovian, CM2
Aronne, L1
Rubino, D1
Still, C1
Wyatt, H1
Burns, C3
Kim, D2
Dunayevich, E7
Smith, SR1
Fujioka, K12
Gupta, AK3
Billes, SK4
Greenway, FL8
White, MA1
Wang, GJ1
Tomasi, D1
Volkow, ND1
Wang, R1
Telang, F1
Caparelli, EC1
Hollander, P1
Plodkowski, R2
Greenway, F1
Bays, H1
Klassen, P2
Sinnayah, P1
Cowley, MA4
Verpeut, JL1
Bello, NT1
Hainer, V1
Citrome, L2
Kalyanasundar, B1
Perez, CI1
Luna, A1
Solorio, J1
Moreno, MG1
Elias, D1
Simon, SA1
Gutierrez, R1
Kolotkin, RL1
Chen, S1
Gilder, K3
Nuffer, W1
Trujillo, JM1
Megyeri, J1
O'Neil, PM3
Hong, K1
Herrmann, K1
Dybala, C1
Lam, H1
Foreyt, JP2
Braverman-Panza, J1
Stefanidis, A1
Man Lee, CC1
Brown, WA1
Oldfield, BJ1
Halseth, A1
Shan, K1
Curry, SA1
Whitehouse, MJ1
Guttadauria, M3
Anderson, JW2
Atkinson, RL1
Gadde, KM7
O'Neil, P1
Schumacher, D1
Smith, D1
Tollefson, GD1
Weber, E1
Plodkowski, RA2
Nguyen, Q1
Sundaram, U1
Nguyen, L1
Chau, DL1
St Jeor, S1
Lee, MW1
Padwal, R1
Tollefson, G1
Erickson, J2
Kaplan, LM1
Wadden, TA2
Foster, GD1
Hill, JO1
Klein, S1
Perri, MG1
Pi-Sunyer, FX1
Rock, CL1
Erickson, JS1
Maier, HN1
Kim, DD2
Mudaliar, S1
Katsiki, N1
Hatzitolios, AI1
Mikhailidis, DP1
Calandra, C1
Russo, RG1
Luca, M1
Makowski, CT1
Gwinn, KM1
Hurren, KM1
Hiatt, WR1
Thomas, A1
Goldfine, AB1
Mercer, SL1
Carter, R1
Mouralidarane, A1
Ray, S1
Soeda, J1
Oben, J1
Jain, AK1
Kaplan, RA1
Allison, DB1
Brewer, ER1
Leadbetter, RA1
Richard, N1
Haight, B1
Jamerson, BD1
Buaron, KS1
Metz, A1
Zhang, W1
Foust, MS2
Xiong, GL1
Yonish, GM1
Wagner, HR2
Parker, CB1
Maner, LG1
Logue, EJ1
Drezner, MK1
Krishnan, KR1
McKenney, J1

Clinical Trials (10)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Multicenter, Randomized, Double Blind, Placebo Controlled Study Comparing the Safety and Efficacy of Naltrexone Sustained Release (SR)/Bupropion Sustained Release (SR) and Placebo in Obese Subjects[NCT00567255]Phase 31,496 participants (Actual)Interventional2007-12-31Completed
Placebo-Controlled Trial of Bupropion for the Treatment of Binge Eating Disorder[NCT00414167]Phase 2/Phase 361 participants (Actual)Interventional2005-12-31Completed
Naltrexone Sustained Release (SR) 32 mg and Bupropion Sustained Release (SR) 360 mg Combination Therapy in Functional Magnetic Resonance Imaging (fMRI) Changes in Overweight or Obese Subjects[NCT00711477]Phase 246 participants (Actual)Interventional2008-09-30Completed
A Multicenter, Randomized, Double Blind, Placebo Controlled Study Comparing the Safety and Efficacy of Naltrexone 32 mg Sustained Release (SR)/Bupropion 360 mg Sustained Release (SR) and Placebo in Obese Subjects With Type 2 Diabetes Mellitus[NCT00474630]Phase 3505 participants (Actual)Interventional2007-05-31Completed
A Multicenter, Randomized, Open-Label, Controlled, Method-of-Use Study Assessing the Effect of Naltrexone Sustained Release (SR)/Bupropion SR on Body Weight and Cardiovascular Risk Factors in Overweight and Obese Subjects (The Ignite Study)[NCT01764386]Phase 3242 participants (Actual)Interventional2013-02-28Completed
Phase II Randomized, Double-Blind Trial of Bupropion Versus Bupropion + Naltrexone for Smoking Cessation[NCT00419731]Phase 2/Phase 3120 participants (Anticipated)Interventional2006-11-30Recruiting
The Beef WISE Study: Beef's Role in Weight Improvement, Satisfaction, and Energy[NCT02627105]120 participants (Actual)Interventional2015-09-30Completed
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Comparing the Safety and Efficacy of Naltrexone Sustained Release (SR)/Bupropion SR and Placebo in Subjects With Obesity Participating in a Behavior Modification Program[NCT00456521]Phase 3793 participants (Actual)Interventional2007-03-31Completed
A Multicenter, Randomized, Double Blind, Placebo Controlled Study Comparing the Safety and Efficacy of Two Doses of Naltrexone Sustained Release (SR)/Bupropion Sustained Release (SR) and Placebo in Obese Subjects[NCT00532779]Phase 31,742 participants (Actual)Interventional2007-10-31Completed
Effect of Sulphate-bicarbonate-calcium Water Consumption on the Body Weight and Gut Microbiota Composition in Overweight and Obese Patients Under Low-calorie Diet[NCT02154230]0 participants (Actual)Interventional2013-11-30Withdrawn (stopped due to failure to enroll)
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Body Weight- Mean Percent Change From Baseline to Week 56

"Beginning at Week 28 through Week 44, NB32-treated subjects who failed to achieve or maintain at least 5% body weight loss from baseline were re-randomized (1:1 ratio) to continue NB32 or begin treatment with a higher dose of naltrexone SR - naltrexone SR 48 mg/bupropion SR 360 mg (referred to as NB48) (daily dose of bupropion SR was 360 mg for NB32 and NB48).The analysis of NB32 vs. placebo at Week 56 was completed using a weighted analysis. This analysis was referred to as the weighted LOCF analysis.~Subjects treated with NB32 who were re-randomized to NB48 were not included. Subjects re-randomized to NB32 were double-weighted and subjects who were not re-randomized were single-weighted. Subjects in the placebo group were single-weighted. The double weighting analysis restored the influence of poor performers at Weeks 28 to 44 in the NB32 group without including any data from the higher dose group (NB48)." (NCT00567255)
Timeframe: Baseline, 56 weeks

Interventionpercentage of body weight (Least Squares Mean)
NB32-6.40
Placebo-1.23

Body Weight- Proportion of Subjects With ≥10% Decrease From Baseline to Week 28

(NCT00567255)
Timeframe: Baseline, 28 weeks

Interventionpercentage of participants (Number)
NB3227.27
Placebo7.02

Body Weight- Proportion of Subjects With ≥5% Decrease From Baseline to Week 56

"Beginning at Week 28 through Week 44, NB32-treated subjects who failed to achieve or maintain at least 5% body weight loss from baseline were re-randomized (1:1 ratio) to continue NB32 or begin treatment with a higher dose of naltrexone SR - naltrexone SR 48 mg/bupropion SR 360 mg (referred to as NB48) (daily dose of bupropion SR was 360 mg for NB32 and NB48).The analysis of NB32 vs. placebo at Week 56 was completed using a weighted analysis. This analysis was referred to as the weighted LOCF analysis.~Subjects treated with NB32 who were re-randomized to NB48 were not included. Subjects re-randomized to NB32 were double-weighted and subjects who were not re-randomized were single-weighted. Subjects in the placebo group were single-weighted. The double weighting analysis restored the influence of poor performers at Weeks 28 to 44 in the NB32 group without including any data from the higher dose group (NB48)." (NCT00567255)
Timeframe: Baseline, 56 weeks

Interventionpercentage of participants (Number)
NB3250.48
Placebo17.11

Change in Diastolic Blood Pressure

(NCT00567255)
Timeframe: Baseline, 28 weeks

Interventionmm Hg (Least Squares Mean)
NB320.20
Placebo-0.67

Change in Fasting Blood Glucose Levels

(NCT00567255)
Timeframe: Baseline, 28 weeks

Interventionmg/dL (Least Squares Mean)
NB32-2.11
Placebo-1.73

Change in Fasting HDL Cholesterol Levels

(NCT00567255)
Timeframe: Baseline, 28 weeks

Interventionmg/dL (Least Squares Mean)
NB321.19
Placebo-1.40

Change in Fasting Insulin Levels, Using Log-transformed Data

(NCT00567255)
Timeframe: Baseline, 28 weeks

Interventionpercent change (Least Squares Mean)
NB32-14.14
Placebo-0.50

Change in Fasting LDL Cholesterol Levels

(NCT00567255)
Timeframe: Baseline, 28 weeks

Interventionmg/dL (Least Squares Mean)
NB32-4.36
Placebo0.00

Change in Fasting Triglycerides Levels, Using Log-transformed Data

(NCT00567255)
Timeframe: Baseline, 28 weeks

Interventionpercent change (Least Squares Mean)
NB32-7.32
Placebo-1.36

Change in Food Craving Inventory Carbohydrates Subscale Score

The Food Craving Inventory is a 33-item self-report measure designed to assess specific food cravings and is organized into 4 subscales (high fats, sweets, carbohydrates/starches, and fast-food fats). A craving was defined as an intense desire to consume a particular food (or food type) that was difficult to resist over the past month. Subjects rated their frequency of cravings for each of the 33 items using a 5-point scale, where 1=never, 2=rarely, 3=sometimes, 4=often, and 5=always. The carbohydrates subscale consisted of 8 items and the score ranges from 8 (better outcome) to 40 (worse outcome). (NCT00567255)
Timeframe: Baseline, 28 weeks

Interventionunits on a scale (Least Squares Mean)
NB32-2.68
Placebo-2.20

Change in Food Craving Inventory Sweets Subscale Score

The Food Craving Inventory is a 33-item self-report measure designed to assess specific food cravings and is organized into 4 subscales (high fats, sweets, carbohydrates/starches, and fast-food fats). A craving was defined as an intense desire to consume a particular food (or food type) that was difficult to resist over the past month. Subjects rated their frequency of cravings for each of the 33 items using a 5-point scale, where 1=never, 2=rarely, 3=sometimes, 4=often, and 5=always. The sweets subscale consisted of 8 items and the score ranges from 8 (better outcome) to 40 (worse outcome). (NCT00567255)
Timeframe: Baseline, 28 weeks

Interventionunits on a scale (Least Squares Mean)
NB32-3.20
Placebo-3.18

Change in High-sensitivity C Reactive Protein (Hs-CRP) Levels, Using Log-transformed Data

(NCT00567255)
Timeframe: Baseline, 28 weeks

Interventionpercent change (Least Squares Mean)
NB32-9.38
Placebo-1.14

Change in HOMA-IR Levels, Using Log-transformed Data

HOMA-IR= Homeostasis Model Assessment-Insulin Resistance (NCT00567255)
Timeframe: Baseline, 28 weeks

Interventionpercent change (Least Squares Mean)
NB32-16.44
Placebo-4.15

Change in IDS-SR Total Score

IDS-SR= Inventory of Depressive Symptoms-Subject Rated IDS-SR total score is based on 30 items. The total score can range from 0-84, with 0 being no depressive symptoms and 84 being very severe depressive symptoms. A total score ≤ 13 indicates no depression. (NCT00567255)
Timeframe: Baseline, 28 weeks

Interventionunits on a scale (Least Squares Mean)
NB32-0.23
Placebo-0.28

Change in IWQOL-Lite Total Scores

IWQOL-Lite= Impact of Weight on Quality of Life-Lite Questionnaire Total score is based on a scale from 0 to 100, with 0 representing the poorest and 100 the best quality of life and where a score of 71-79 indicates moderate impairment (NCT00567255)
Timeframe: Baseline, 28 weeks

Interventionunits on a scale (Least Squares Mean)
NB329.94
Placebo6.17

Change in Question 19 From 21-Item COE (Control of Eating) Questionnaire

Question 19: Generally, how difficult has it been to control your eating? Scoring: 0=not at all difficult; 100=extremely difficult (NCT00567255)
Timeframe: Baseline, 28 weeks

Interventionunits on a scale (Least Squares Mean)
NB32-18.32
Placebo-11.09

Change in Systolic Blood Pressure

(NCT00567255)
Timeframe: Baseline, 28 weeks

Interventionmm Hg (Least Squares Mean)
NB32-0.93
Placebo-1.23

Change in Waist Circumference

(NCT00567255)
Timeframe: Baseline, 28 weeks

Interventioncm (Least Squares Mean)
NB32-6.16
Placebo-2.74

Co-primary: Body Weight- Mean Percent Change From Baseline to Week 28

(NCT00567255)
Timeframe: Baseline, 28 weeks

Interventionpercentage of body weight (Least Squares Mean)
NB32-6.45
Placebo-1.89

Co-primary: Body Weight- Proportion of Subjects With ≥5% Decrease From Baseline to Week 28

(NCT00567255)
Timeframe: Baseline, 28 weeks

Interventionpercentage of participants (Number)
NB3255.64
Placebo17.54

Frequency of Binge Eating Episodes

(NCT00414167)
Timeframe: One week (at post treatment)

Interventionepisodes/week (Mean)
Bupropion0.8
Placebo1.0

Percent BMI Loss

Percent loss in Body Mass Index (NCT00414167)
Timeframe: 8 weeks (baseline and 8 weeks)

InterventionPercent loss (Mean)
Bupropion1.8
Placebo0.6

Change in Question 19 From 21-Item COE (Control of Eating) Questionnaire

Question 19: Generally, how difficult has it been to control your eating? Scoring: 0=not at all difficult; 100=extremely difficult (NCT00711477)
Timeframe: Baseline, 4 weeks

Interventionunits on a scale (Least Squares Mean)
NB32-13.55
Placebo-4.14

Dutch Eating Behavior Questionnaire - Change in Emotional Eating A Subscale Score

The Dutch Eating Behavior Questionnaire is a 33-item self-report measure designed to assess the type of eating behavior and is organized into 3 subscales (emotional eating, externally-induced eating, and restrained eating). Subjects rated the frequency of their eating behaviors using a 5-point scale, where 1=never, 2=seldom, 3=sometimes, 4=often, and 5=very often. The Emotional Eating A subscale (clearly labeled emotions) consisted of 9 items and the scores ranged from 9 (better outcome) to 45 (worse outcome). (NCT00711477)
Timeframe: Baseline, 4 weeks

Interventionunits on a scale (Least Squares Mean)
NB32-1.16
Placebo0.48

Dutch Eating Behavior Questionnaire - Change in Emotional Eating B Subscale Score

The Dutch Eating Behavior Questionnaire is a 33-item self-report measure designed to assess the type of eating behavior and is organized into 3 subscales (emotional eating, externally-induced eating, and restrained eating). Subjects rated the frequency of their eating behaviors using a 5-point scale, where 1=never, 2=seldom, 3=sometimes, 4=often, and 5=very often. The Emotional Eating B subscale (diffuse emotions) consisted of 4 items and the scores ranged from 4 (better outcome) to 20 (worse outcome). (NCT00711477)
Timeframe: Baseline, 4 weeks

Interventionunits on a scale (Least Squares Mean)
NB32-0.90
Placebo0.45

Dutch Eating Behavior Questionnaire - Change in External Eating Subscale Score

The Dutch Eating Behavior Questionnaire is a 33-item self-report measure designed to assess the type of eating behavior and is organized into 3 subscales (emotional eating, externally-induced eating, and restrained eating). Subjects rated the frequency of their eating behaviors using a 5-point scale where 1=never, 2=seldom, 3=sometimes, 4=often, and 5=very often. The External Eating subscale consisted of 10 items and the scores ranged from 10 (better outcome) to 50 (worse outcome). (NCT00711477)
Timeframe: Baseline, 4 weeks

Interventionunits on a scale (Least Squares Mean)
NB32-2.64
Placebo-0.16

Dutch Eating Behavior Questionnaire - Change in Restrained Eating Subscale Score

The Dutch Eating Behavior Questionnaire is a 33-item self-report measure designed to assess the type of eating behavior and is organized into 3 subscales (emotional eating, externally-induced eating, and restrained eating). Subjects rated the frequency of their eating behaviors using a 5-point scale, where 1=never, 2=seldom, 3=sometimes, 4=often, and 5=very often. The Restrained Eating subscale consisted of 10 items and the scores ranged from 10 (worse outcome) to 50 (better outcome). (NCT00711477)
Timeframe: Baseline, 4 weeks

Interventionunits on a scale (Least Squares Mean)
NB321.47
Placebo1.87

Percent Change in Body Weight

(NCT00711477)
Timeframe: Baseline, 4 weeks

Interventionpercentage of body weight (Least Squares Mean)
NB32-0.99
Placebo-0.43

Response to Food Related Cues Using Functional Magnetic Resonance Imaging - Anterior Cingulate

Assessment of differences in brain activation in response to food cues before and after 4 weeks of treatment in subjects receiving NB or placebo. (NCT00711477)
Timeframe: Baseline, 4 weeks

Interventionpercent activation (Mean)
Placebo-0.42
NB320.16

Response to Food Related Cues Using Functional Magnetic Resonance Imaging - Hippocampal Region 1

Assessment of differences in brain activation in response to food cues before and after 4 weeks of treatment in subjects receiving NB or placebo. (NCT00711477)
Timeframe: Baseline, 4 weeks

Interventionpercent activation (Mean)
Placebo-0.16
NB320.60

Response to Food Related Cues Using Functional Magnetic Resonance Imaging - Hippocampal Region 2

Assessment of differences in brain activation in response to food cues before and after 4 weeks of treatment in subjects receiving NB or placebo. (NCT00711477)
Timeframe: Baseline, 4 weeks

Interventionpercent activation (Mean)
Placebo-0.79
NB320.21

Response to Food Related Cues Using Functional Magnetic Resonance Imaging - Posterior Insula

Assessment of differences in brain activation in response to food cues before and after 4 weeks of treatment in subjects receiving NB or placebo. (NCT00711477)
Timeframe: Baseline, 4 weeks

Interventionpercent activation (Mean)
Placebo-0.16
NB320.30

Response to Food Related Cues Using Functional Magnetic Resonance Imaging - Superior Frontal

Assessment of differences in brain activation in response to food cues before and after 4 weeks of treatment in subjects receiving NB or placebo. (NCT00711477)
Timeframe: Baseline, 4 weeks

Interventionpercent activation (Mean)
Placebo-0.35
NB320.34

Response to Food Related Cues Using Functional Magnetic Resonance Imaging - Superior Parietal

Assessment of differences in brain activation in response to food cues before and after 4 weeks of treatment in subjects receiving NB or placebo. (NCT00711477)
Timeframe: Baseline, 4 weeks

Interventionpercent activation (Mean)
Placebo-0.56
NB320.74

Body Weight- Proportion of Subjects With ≥10% Decrease

(NCT00474630)
Timeframe: Baseline, 56 weeks

Interventionpercentage of participants (Number)
NB3218.49
Placebo5.66

Change in Diastolic Blood Pressure

(NCT00474630)
Timeframe: Baseline, 56 weeks

Interventionmm Hg (Least Squares Mean)
NB32-1.06
Placebo-1.47

Change in Fasting Blood Glucose Levels

(NCT00474630)
Timeframe: Baseline, 56 weeks

Interventionmg/dL (Least Squares Mean)
NB32-11.87
Placebo-4.02

Change in Fasting HDL Cholesterol Levels

(NCT00474630)
Timeframe: Baseline, 56 weeks

Interventionmg/dL (Least Squares Mean)
NB323.03
Placebo-0.29

Change in Fasting Insulin Levels, Using Log-transformed Data

(NCT00474630)
Timeframe: Baseline, 56 weeks

Interventionpercent change (Least Squares Mean)
NB32-13.48
Placebo-10.35

Change in Fasting LDL Cholesterol Levels

(NCT00474630)
Timeframe: Baseline, 56 weeks

Interventionmg/dL (Least Squares Mean)
NB32-1.44
Placebo-0.01

Change in Fasting Triglycerides Levels, Using Log-transformed Data

(NCT00474630)
Timeframe: Baseline, 56 weeks

Interventionpercent change (Least Squares Mean)
NB32-11.20
Placebo-0.80

Change in Food Craving Inventory Carbohydrates Subscale Score

The Food Craving Inventory is a 33-item self-report measure designed to assess specific food cravings and is organized into 4 subscales (high fats, sweets, carbohydrates/starches, and fast-food fats). A craving was defined as an intense desire to consume a particular food (or food type) that was difficult to resist over the past month. Subjects rated their frequency of cravings for each of the 33 items using a 5-point scale, where 1=never, 2=rarely, 3=sometimes, 4=often, and 5=always. The carbohydrates subscale consisted of 8 items and the score ranges from 8 (better outcome) to 40 (worse outcome). (NCT00474630)
Timeframe: Baseline, 56 weeks

Interventionunits on a scale (Least Squares Mean)
NB32-1.48
Placebo-1.52

Change in Food Craving Inventory Sweets Subscale Score

The Food Craving Inventory is a 33-item self-report measure designed to assess specific food cravings and is organized into 4 subscales (high fats, sweets, carbohydrates/starches, and fast-food fats). A craving was defined as an intense desire to consume a particular food (or food type) that was difficult to resist over the past month. Subjects rated their frequency of cravings for each of the 33 items using a 5-point scale, where 1=never, 2=rarely, 3=sometimes, 4=often, and 5=always. The sweets subscale consisted of 8 items and the score ranges from 8 (better outcome) to 40 (worse outcome). (NCT00474630)
Timeframe: Baseline, 56 weeks

Interventionunits on a scale (Least Squares Mean)
NB32-1.97
Placebo-2.40

Change in HbA1c Levels

(NCT00474630)
Timeframe: Baseline, 56 weeks

Interventionpercent (Least Squares Mean)
NB32-0.63
Placebo-0.14

Change in High-sensitivity C Reactive Protein (Hs-CRP) Levels, Using Log-transformed Data

(NCT00474630)
Timeframe: Baseline, 56 weeks

Interventionpercent change (Least Squares Mean)
NB32-20.91
Placebo-13.29

Change in HOMA-IR Levels, Using Log-transformed Data

HOMA-IR= Homeostasis Model Assessment-Insulin Resistance (NCT00474630)
Timeframe: Baseline, 56 weeks

Interventionpercent change (Least Squares Mean)
NB32-20.56
Placebo-14.67

Change in IDS-SR Total Scores

IDS-SR= Inventory of Depressive Symptoms-Subject Rated IDS-SR total score is based on 30 items. The total score can range from 0-84, with 0 being no depressive symptoms and 84 being very severe depressive symptoms. A total score ≤ 13 indicates no depression. (NCT00474630)
Timeframe: Baseline, 56 weeks

Interventionunits on a scale (Least Squares Mean)
NB320.01
Placebo-1.60

Change in IWQOL-Lite Total Scores

IWQOL-Lite= Impact of Weight on Quality of Life-Lite Questionnaire Total score is based on a scale from 0 to 100, with 0 representing the poorest and 100 the best quality of life and where a score of 71-79 indicates moderate impairment (NCT00474630)
Timeframe: Baseline, 56 weeks

Interventionunits on a scale (Least Squares Mean)
NB329.27
Placebo7.90

Change in Question 19 From 21-Item COE (Control of Eating) Questionnaire

Question 19: Generally, how difficult has it been to control your eating? Scoring: 0=not at all difficult; 100=extremely difficult (NCT00474630)
Timeframe: Baseline, 56 weeks

Interventionunits on a scale (Least Squares Mean)
NB32-11.89
Placebo-6.91

Change in Systolic Blood Pressure

(NCT00474630)
Timeframe: Baseline, 56 weeks

Interventionmm Hg (Least Squares Mean)
NB320.03
Placebo-1.12

Change in Waist Circumference

(NCT00474630)
Timeframe: Baseline, 56 weeks

Interventioncm (Least Squares Mean)
NB32-4.97
Placebo-2.89

Co-primary: Body Weight- Mean Percent Change

(NCT00474630)
Timeframe: Baseline, 56 weeks

Interventionpercentage of body weight (Least Squares Mean)
NB32-5.03
Placebo-1.75

Co-primary: Body Weight- Proportion of Subjects With ≥5% Decrease

(NCT00474630)
Timeframe: Baseline, 56 weeks

Interventionpercentage of participants (Number)
NB3244.53
Placebo18.87

HbA1c- Proportion of Subjects With HbA1c <6.5% at Endpoint

(NCT00474630)
Timeframe: Baseline, 56 weeks

Interventionpercentage of participants (Number)
NB3220.72
Placebo10.22

HbA1c- Proportion of Subjects With HbA1c <7% at Endpoint

(NCT00474630)
Timeframe: Baseline, 56 weeks

Interventionpercentage of participants (Number)
NB3244.14
Placebo26.28

Percent of Subjects Discontinuing Due to Poor Glycemic Control

Due to pre-specified hypothesis testing design, no formal statistical inference testing was performed. Odds ratio not calculated as there were no subjects in the NB32 group that discontinued due to poor glycemic control. (NCT00474630)
Timeframe: Baseline, 56 weeks

Interventionpercentage of participants (Number)
NB320
Placebo1.89

Percent of Subjects Requiring Rescue Medications for Diabetes

(NCT00474630)
Timeframe: Baseline, 56 weeks

Interventionpercentage of participants (Number)
NB3222.26
Placebo35.22

Percent of Subjects With Dose Increase in Oral Antidiabetes Medications

(NCT00474630)
Timeframe: Baseline, 56 weeks

Interventionpercentage of participants (Number)
NB323.02
Placebo1.26

Percent of Subjects With Dose Reduction in Oral Antidiabetes Medications

(NCT00474630)
Timeframe: Baseline, 56 weeks

Interventionpercentage of participants (Number)
NB321.89
Placebo1.26

Absolute Change in Body Weight From Baseline to Week 26

(NCT01764386)
Timeframe: Baseline to Week 26

Interventionkg (Least Squares Mean)
NB + CLI-9.7
Usual Care-1.0

Change Fasting Insulin From Baseline to Week 26

(NCT01764386)
Timeframe: Baseline to Week 26

InterventionuIU/mL (Least Squares Mean)
NB + CLI-7.5
Usual Care-3.4

Change in Diastolic Blood Pressure From Baseline to Week 26

(NCT01764386)
Timeframe: Baseline to Week 26

Interventionmm Hg (Least Squares Mean)
NB + CLI-1.7
Usual Care-1.3

Change in Fasting High-density Lipoprotein Cholesterol From Baseline to Week 26

(NCT01764386)
Timeframe: Baseline to Week 26

Interventionmg/dL (Least Squares Mean)
NB + CLI4.1
Usual Care0.1

Change in Fasting Low-density Lipoprotein Cholesterol From Baseline to Week 26

(NCT01764386)
Timeframe: Baseline to Week 26

Interventionmg/dL (Least Squares Mean)
NB + CLI-2.0
Usual Care-1.9

Change in Fasting Plasma Glucose From Baseline to Week 26

(NCT01764386)
Timeframe: Baseline to Week 26

Interventionmg/dL (Least Squares Mean)
NB + CLI-2.9
Usual Care1.6

Change in Fasting Triglycerides From Baseline to Week 26

(NCT01764386)
Timeframe: Baseline to Week 26

Interventionmg/dL (Least Squares Mean)
NB + CLI-13.6
Usual Care2.8

Change in Heart Rate From Baseline to Week 26

(NCT01764386)
Timeframe: Baseline to Week 26

Interventionbpm (Least Squares Mean)
NB + CLI1.7
Usual Care-0.3

Change in Homeostasis Model Assessment-insulin Resistance (HOMA-IR) From Baseline to Week 26

HOMA-IR is an insulin sensitivity index that is calculated as HOMA-IR = (Glucose * Insulin) / 405, where glucose is in mass units (mg/dL) and insulin is in µIU/mL. Higher values indicate lower insulin sensitivity. (NCT01764386)
Timeframe: Baseline to Week 26

Interventionunits on a scale (Least Squares Mean)
NB + CLI-2.0
Usual Care-0.8

Change in Patient-reported Arizona Sexual Experiences Scale (ASEX) Total Scores From Baseline to Week 26

Arizona Sexual Experiences (ASEX) scale is a 5-item rating scale that quantifies sex drive, arousal, vaginal lubrication/penile erection, ability to reach orgasm, and satisfaction from orgasm. Possible total scores range from 5 to 30, with the higher scores indicating more sexual dysfunction. (NCT01764386)
Timeframe: Baseline to Week 26

Interventionunits on a scale (Least Squares Mean)
NB + CLI-2.2
Usual Care-0.1

Change in Patient-reported Binge Eating Scale (BES) Total Scores From Baseline to Week 26

The BES is a 16-item questionnaire that identifies different levels of binge-eating severity, with total scores ranging between 0-46. BES scores were categorized as follows: None = Scores ≤17 indicated no significant binge eating, Moderate = scores from 18 to 26 (inclusive), Severe = scores ≥27 indicated severe levels of binge eating. (NCT01764386)
Timeframe: Baseline to Week 26

Interventionunits on a scale (Least Squares Mean)
NB + CLI-6.8
Usual Care1.1

Change in Patient-reported Impact of Weight on Quality of Life-Lite Questionnaire (IWQOL-Lite) Total Score From Baseline to Week 26

Impact of Weight on Quality of Life-Lite Questionnaire (IWQOL-Lite) is a self-reported assessment of perceived effect of weight on quality of life. It consists of 31 items organized in 5 domains (physical function, self-esteem, sexual life, public distress and work). IWQOL-Lite total score is based on a scale from 0 to 100, with 0 representing the poorest and 100 the best quality of life and where a score of 71-79 indicates moderate impairment. (NCT01764386)
Timeframe: Baseline to Week 26

Interventionunits on a scale (Least Squares Mean)
NB + CLI16.4
Usual Care-1.0

Change in Systolic Blood Pressure From Baseline to Week 26

(NCT01764386)
Timeframe: Baseline to Week 26

Interventionmm Hg (Least Squares Mean)
NB + CLI-4.8
Usual Care-2.8

Change in Waist Circumference From Baseline to Week 26

(NCT01764386)
Timeframe: Baseline to Week 26

Interventioncm (Least Squares Mean)
NB + CLI-6.96
Usual Care-1.64

Percent Change in Body Weight From Baseline (Day 1) to Week 26

(NCT01764386)
Timeframe: Baseline to Week 26

Interventionpercent change in body weight (Least Squares Mean)
NB + CLI-9.46
Usual Care-0.94

Percentage of Subjects Achieving a Loss of at Least 10% of Baseline Body Weight at Week 26

(NCT01764386)
Timeframe: Baseline to Week 26

Interventionpercentage of participants (Number)
NB + CLI42.3
Usual Care3.7

Percentage of Subjects Achieving a Loss of at Least 15% of Baseline Body Weight at Week 26

(NCT01764386)
Timeframe: Baseline to Week 26

Interventionpercentage of participants (Number)
NB + CLI12.7
Usual Care0.0

Percentage of Subjects Achieving a Loss of at Least 5% of Baseline Body Weight at Week 26

(NCT01764386)
Timeframe: Baseline to Week 26

Interventionpercentage of participants (Number)
NB + CLI84.5
Usual Care12.2

Body Weight- Proportion of Subjects With ≥10% Decrease

(NCT00456521)
Timeframe: Baseline, 56 weeks

Interventionpercentage of participants (Number)
NB3241.49
Placebo20.21

Change in Diastolic Blood Pressure

(NCT00456521)
Timeframe: Baseline, 56 weeks

InterventionmmHg (Least Squares Mean)
NB32-1.41
Placebo-2.78

Change in Fasting Blood Glucose Levels

(NCT00456521)
Timeframe: Baseline, 56 weeks

Interventionmg/dL (Least Squares Mean)
NB32-2.36
Placebo-1.08

Change in Fasting HDL Cholesterol Levels

(NCT00456521)
Timeframe: Baseline, 56 weeks

Interventionmg/dL (Least Squares Mean)
NB324.10
Placebo0.87

Change in Fasting Insulin Levels, Using Log-transformed Data

(NCT00456521)
Timeframe: Baseline, 56 weeks

Interventionpercent change (Least Squares Mean)
NB32-27.98
Placebo-15.45

Change in Fasting LDL Cholesterol

(NCT00456521)
Timeframe: Baseline, 56 weeks

Interventionmg/dL (Least Squares Mean)
NB325.43
Placebo8.13

Change in Fasting Triglycerides Levels, Using Log-transformed Data

(NCT00456521)
Timeframe: Baseline, 56 weeks

Interventionpercent change (Least Squares Mean)
NB32-16.62
Placebo-8.51

Change in Food Craving Inventory Carbohydrates Subscale Scores

The Food Craving Inventory is a 33-item self-report measure designed to assess specific food cravings and is organized into 4 subscales (high fats, sweets, carbohydrates/starches, and fast-food fats). A craving was defined as an intense desire to consume a particular food (or food type) that was difficult to resist over the past month. Subjects rated their frequency of cravings for each of the 33 items using a 5-point scale, where 1=never, 2=rarely, 3=sometimes, 4=often, and 5=always. The carbohydrates subscale consisted of 8 items and the score ranges from 8 (better outcome) to 40 (worse outcome). (NCT00456521)
Timeframe: Baseline, 56 weeks

Interventionunits on a scale (Least Squares Mean)
NB32-2.06
Placebo-1.97

Change in Food Craving Inventory Sweets Subscale Scores

The Food Craving Inventory is a 33-item self-report measure designed to assess specific food cravings and is organized into 4 subscales (high fats, sweets, carbohydrates/starches, and fast-food fats). A craving was defined as an intense desire to consume a particular food (or food type) that was difficult to resist over the past month. Subjects rated their frequency of cravings for each of the 33 items using a 5-point scale, where 1=never, 2=rarely, 3=sometimes, 4=often, and 5=always. The sweets subscale consisted of 8 items and the score ranges from 8 (better outcome) to 40 (worse outcome). (NCT00456521)
Timeframe: Baseline, 56 weeks

Interventionunits on a scale (Least Squares Mean)
NB32-2.54
Placebo-2.43

Change in High-sensitivity C Reactive Protein (Hs-CRP) Levels, Using Log-transformed Data

(NCT00456521)
Timeframe: Baseline, 56 weeks

Interventionpercent change (Least Squares Mean)
NB32-25.87
Placebo-16.89

Change in HOMA-IR Levels, Using Log-transformed Data

HOMA-IR= Homeostasis Model Assessment-Insulin Resistance (NCT00456521)
Timeframe: Baseline, 56 weeks

Interventionpercent change (Least Squares Mean)
NB32-29.93
Placebo-16.56

Change in IDS-SR Total Scores

IDS-SR= Inventory of Depressive Symptoms-Subject Rated IDS-SR total score is based on 30 items. The total score can range from 0-84, with 0 being no depressive symptoms and 84 being very severe depressive symptoms. A total score ≤ 13 indicates no depression. (NCT00456521)
Timeframe: Baseline, 56 weeks

Interventionunits on a scale (Least Squares Mean)
NB320.09
Placebo-0.00

Change in IWQOL-Lite Total Scores

IWQOL-Lite= Impact of Weight on Quality of Life-Lite Questionnaire Total score is based on a scale from 0 to 100, with 0 representing the poorest and 100 the best quality of life and where a score of 71-79 indicates moderate impairment (NCT00456521)
Timeframe: Baseline, 56 weeks

Interventionunits on a scale (Least Squares Mean)
NB3213.43
Placebo10.29

Change in Question 19 From 21-Item COE (Control of Eating) Questionnaire

Question 19: Generally, how difficult has it been to control your eating? Scoring: 0=not at all difficult; 100=extremely difficult (NCT00456521)
Timeframe: Baseline, 56 weeks

Interventionunits on a scale (Least Squares Mean)
NB32-13.75
Placebo-8.46

Change in Systolic Blood Pressure

(NCT00456521)
Timeframe: Baseline, 56 weeks

InterventionmmHg (Least Squares Mean)
NB32-1.32
Placebo-3.87

Change in Waist Circumference

(NCT00456521)
Timeframe: Baseline, 56 weeks

Interventioncm (Least Squares Mean)
NB32-9.98
Placebo-6.77

Co-primary: Body Weight- Mean Percent Change

(NCT00456521)
Timeframe: Baseline, 56 weeks

Interventionpercentage of body weight (Least Squares Mean)
NB32-9.29
Placebo-5.08

Co-primary: Body Weight- Proportion of Subjects With ≥5% Decrease

(NCT00456521)
Timeframe: Baseline, 56 weeks

Interventionpercentage of participants (Number)
NB3266.39
Placebo42.49

Body Weight- Proportion of Subjects With ≥10% Decrease

(NCT00532779)
Timeframe: Baseline, 56 weeks

InterventionPercentage of participants (Number)
NB1620.17
NB3224.63
Placebo7.44

Change in Diastolic Blood Pressure

(NCT00532779)
Timeframe: Baseline, 56 weeks

Interventionmm Hg (Least Squares Mean)
NB160.09
NB320.04
Placebo-0.86

Change in Fasting Blood Glucose Levels

(NCT00532779)
Timeframe: Baseline, 56 weeks

Interventionmg/dL (Least Squares Mean)
NB16-2.39
NB32-3.24
Placebo-1.30

Change in Fasting HDL Cholesterol Levels

(NCT00532779)
Timeframe: Baseline, 56 weeks

Interventionmg/dL (Least Squares Mean)
NB163.36
NB323.42
Placebo-0.06

Change in Fasting Insulin Levels, Using Log-transformed Data

(NCT00532779)
Timeframe: Baseline, 56 weeks

Interventionpercent change (Least Squares Mean)
NB16-11.84
NB32-17.14
Placebo-4.57

Change in Fasting LDL Cholesterol Levels

(NCT00532779)
Timeframe: Baseline, 56 weeks

Interventionmg/dL (Least Squares Mean)
NB16-3.67
NB32-4.41
Placebo-3.28

Change in Fasting Triglycerides Levels, Using Log-transformed Data

(NCT00532779)
Timeframe: Baseline, 56 weeks

Interventionpercent change (Least Squares Mean)
NB16-7.96
NB32-12.69
Placebo-3.08

Change in Food Craving Inventory Carbohydrates Subscale Score

The Food Craving Inventory is a 33-item self-report measure designed to assess specific food cravings and is organized into 4 subscales (high fats, sweets, carbohydrates/starches, and fast-food fats). A craving was defined as an intense desire to consume a particular food (or food type) that was difficult to resist over the past month. Subjects rated their frequency of cravings for each of the 33 items using a 5-point scale, where 1=never, 2=rarely, 3=sometimes, 4=often, and 5=always. The carbohydrates subscale consisted of 8 items and the score ranges from 8 (better outcome) to 40 (worse outcome). (NCT00532779)
Timeframe: Baseline, 56 weeks

Interventionunits on a scale (Least Squares Mean)
NB16-1.85
NB32-2.11
Placebo-1.84

Change in Food Craving Inventory Sweets Subscale Score

The Food Craving Inventory is a 33-item self-report measure designed to assess specific food cravings and is organized into 4 subscales (high fats, sweets, carbohydrates/starches, and fast-food fats). A craving was defined as an intense desire to consume a particular food (or food type) that was difficult to resist over the past month. Subjects rated their frequency of cravings for each of the 33 items using a 5-point scale, where 1=never, 2=rarely, 3=sometimes, 4=often, and 5=always. The sweets subscale consisted of 8 items and the score ranges from 8 (better outcome) to 40 (worse outcome). (NCT00532779)
Timeframe: Baseline, 56 weeks

Interventionunits on a scale (Least Squares Mean)
NB16-2.08
NB32-2.62
Placebo-2.77

Change in High-sensitivity C Reactive Protein (Hs-CRP) Levels, Using Log-transformed Data

(NCT00532779)
Timeframe: Baseline, 56 weeks

Interventionpercent change (Least Squares Mean)
NB16-28.02
NB32-28.98
Placebo-16.66

Change in HOMA-IR Levels, Using Log-transformed Data

HOMA-IR= Homeostasis Model Assessment-Insulin Resistance (NCT00532779)
Timeframe: Baseline, 56 weeks

Interventionpercent change (Least Squares Mean)
NB16-14.33
NB32-20.19
Placebo-5.90

Change in IDS-SR Total Scores

IDS-SR= Inventory of Depressive Symptoms-Subject Rated IDS-SR total score is based on 30 items. The total score can range from 0-84, with 0 being no depressive symptoms and 84 being very severe depressive symptoms. A total score ≤ 13 indicates no depression. (NCT00532779)
Timeframe: Baseline, 56 weeks

Interventionunits on a scale (Least Squares Mean)
NB160.02
NB32-0.27
Placebo-0.72

Change in IWQOL-Lite Total Scores

IWQOL-Lite= Impact of Weight on Quality of Life-Lite Questionnaire Total score is based on a scale from 0 to 100, with 0 representing the poorest and 100 the best quality of life and where a score of 71-79 indicates moderate impairment (NCT00532779)
Timeframe: Baseline, 56 weeks

Interventionunits on a scale (Least Squares Mean)
NB1611.68
NB3212.69
Placebo8.55

Change in Question 19 From 21-Item COE (Control of Eating) Questionnaire

Question 19: Generally, how difficult has it been to control your eating? Scoring: 0=not at all difficult; 100=extremely difficult (NCT00532779)
Timeframe: Baseline, 56 weeks

Interventionunits on a scale (Least Squares Mean)
NB16-12.49
NB32-14.52
Placebo-8.68

Change in Systolic Blood Pressure

(NCT00532779)
Timeframe: Baseline, 56 weeks

Interventionmm Hg (Least Squares Mean)
NB160.29
NB32-0.11
Placebo-1.94

Change in Waist Circumference

(NCT00532779)
Timeframe: Baseline, 56 weeks

Interventioncm (Least Squares Mean)
NB16-5.04
NB32-6.24
Placebo-2.46

Co-primary: Body Weight- Mean Percent Change

(NCT00532779)
Timeframe: Baseline, 56 weeks

Interventionpercentage of body weight (Least Squares Mean)
NB16-5.00
NB32-6.14
Placebo-1.33

Co-primary: Body Weight- Proportion of Subjects With ≥5% Decrease

(NCT00532779)
Timeframe: Baseline, 56 weeks

Interventionpercentage of participants (Number)
NB1639.49
NB3247.98
Placebo16.44

Reviews

23 reviews available for bupropion and Weight Loss

ArticleYear
Pharmacogenetic interactions of medications administered for weight loss in adults: a systematic review and meta-analysis.
    Pharmacogenomics, 2023, Volume: 24, Issue:5

    Topics: Adult; Bupropion; Diabetes Mellitus, Type 2; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Recept

2023
Obesity: The New Global Epidemic Pharmacological Treatment, Opportunities and Limits for Personalized Therapy.
    Endocrine, metabolic & immune disorders drug targets, 2020, Volume: 20, Issue:8

    Topics: Anti-Obesity Agents; Bupropion; Epidemics; Global Health; Humans; Liraglutide; Naltrexone; Obesity;

2020
Long-Term Efficacy and Safety of Anti-Obesity Treatment: Where Do We Stand?
    Current obesity reports, 2021, Volume: 10, Issue:1

    Topics: Animals; Anti-Obesity Agents; Benzazepines; Bupropion; Humans; Liraglutide; Naltrexone; Obesity; Orl

2021
Cardiovascular safety of naltrexone and bupropion therapy: Systematic review and meta-analyses.
    Obesity reviews : an official journal of the International Association for the Study of Obesity, 2021, Volume: 22, Issue:6

    Topics: Bupropion; Child; Female; Humans; Male; Naltrexone; Randomized Controlled Trials as Topic; Smoking C

2021
Gender-related issues in the pharmacology of new anti-obesity drugs.
    Obesity reviews : an official journal of the International Association for the Study of Obesity, 2019, Volume: 20, Issue:3

    Topics: Anti-Obesity Agents; Benzazepines; Bupropion; Dose-Response Relationship, Drug; Drug Combinations; F

2019
The Role of Antiobesity Agents in the Management of Polycystic Ovary Syndrome.
    Folia medica, 2018, Dec-01, Volume: 60, Issue:4

    Topics: Androgens; Anti-Obesity Agents; Bupropion; Drug Combinations; Female; Humans; Insulin Resistance; Li

2018
Naltrexone/bupropion for obesity: an investigational combination pharmacotherapy for weight loss.
    Pharmacological research, 2014, Volume: 84

    Topics: Antidepressive Agents, Second-Generation; Bupropion; Drug Therapy, Combination; Energy Metabolism; H

2014
Drug safety evaluation of naltrexone/bupropion for the treatment of obesity.
    Expert opinion on drug safety, 2014, Volume: 13, Issue:6

    Topics: Animals; Anti-Obesity Agents; Bupropion; Delayed-Action Preparations; Drug Combinations; Humans; Nal

2014
Overview of new antiobesity drugs.
    Expert opinion on pharmacotherapy, 2014, Volume: 15, Issue:14

    Topics: Anti-Obesity Agents; Benzazepines; Benzoxazines; Bupropion; Drug Combinations; Fructose; Glucagon-Li

2014
Safety and tolerability of medications approved for chronic weight management.
    Obesity (Silver Spring, Md.), 2015, Volume: 23 Suppl 1

    Topics: Anti-Obesity Agents; Benzazepines; Bupropion; Delayed-Action Preparations; Drug-Related Side Effects

2015
Current and emerging medications for overweight or obesity in people with comorbidities.
    Diabetes, obesity & metabolism, 2015, Volume: 17, Issue:11

    Topics: Anti-Obesity Agents; Bupropion; Cinnamates; Comorbidity; Cyclohexanes; Diabetes Mellitus; Dyslipidem

2015
Naltrexone/bupropion for the treatment of obesity and obesity with Type 2 diabetes.
    Future cardiology, 2016, Volume: 12, Issue:2

    Topics: Adult; Anti-Obesity Agents; Bupropion; Diabetes Mellitus, Type 2; Drug Combinations; Humans; Naltrex

2016
A Comparison of New Pharmacological Agents for the Treatment of Obesity.
    The Annals of pharmacotherapy, 2016, Volume: 50, Issue:5

    Topics: Anti-Obesity Agents; Benzazepines; Bupropion; Clinical Trials, Phase III as Topic; Drug Combinations

2016
Bupropion and naltrexone: a review of their use individually and in combination for the treatment of obesity.
    Expert opinion on pharmacotherapy, 2009, Volume: 10, Issue:6

    Topics: Animals; Bupropion; Chemistry, Pharmaceutical; Clinical Trials, Phase III as Topic; Drug Therapy, Co

2009
Naltrexone for the treatment of obesity: review and update.
    Expert opinion on pharmacotherapy, 2009, Volume: 10, Issue:11

    Topics: Animals; Bupropion; Dopamine Uptake Inhibitors; Drug Therapy, Combination; Feeding Behavior; Humans;

2009
Contrave, a bupropion and naltrexone combination therapy for the potential treatment of obesity.
    Current opinion in investigational drugs (London, England : 2000), 2009, Volume: 10, Issue:10

    Topics: Administration, Oral; Animals; Appetite; Bupropion; Controlled Clinical Trials as Topic; Delayed-Act

2009
Pharmacologic therapies for obesity.
    Gastroenterology clinics of North America, 2010, Volume: 39, Issue:1

    Topics: Anti-Obesity Agents; Appetite Depressants; Bariatric Surgery; Benzazepines; Bupropion; Cyclobutanes;

2010
Naltrexone sustained-release (SR) + bupropion SR combination therapy for the treatment of obesity: 'a new kid on the block'?
    Annals of medicine, 2011, Volume: 43, Issue:4

    Topics: Bupropion; Clinical Trials, Phase III as Topic; Delayed-Action Preparations; Diabetes Mellitus, Type

2011
Combination therapy with naltrexone and bupropion for obesity.
    Expert opinion on pharmacotherapy, 2011, Volume: 12, Issue:11

    Topics: Animals; Bupropion; Dopamine Uptake Inhibitors; Drug Combinations; Humans; Naltrexone; Narcotic Anta

2011
Naltrexone/bupropion: an investigational combination for weight loss and maintenance.
    Obesity facts, 2011, Volume: 4, Issue:6

    Topics: Anti-Obesity Agents; Bupropion; Diabetes Mellitus; Drug Therapy, Combination; Glycated Hemoglobin; H

2011
ACS chemical neuroscience molecule spotlight on contrave.
    ACS chemical neuroscience, 2011, Sep-21, Volume: 2, Issue:9

    Topics: Anti-Obesity Agents; Bupropion; Clinical Trials, Phase III as Topic; Double-Blind Method; Drug Appro

2011
Recent advancements in drug treatment of obesity.
    Clinical medicine (London, England), 2012, Volume: 12, Issue:5

    Topics: Anti-Obesity Agents; Benzazepines; Benzoxazines; Bupropion; Clinical Trials as Topic; Drug Combinati

2012
Bupropion for weight reduction.
    Expert review of neurotherapeutics, 2007, Volume: 7, Issue:1

    Topics: Antidepressive Agents, Second-Generation; Bupropion; Clinical Trials as Topic; Dose-Response Relatio

2007

Trials

19 trials available for bupropion and Weight Loss

ArticleYear
Naltrexone-Bupropion and Behavior Therapy, Alone and Combined, for Binge-Eating Disorder: Randomized Double-Blind Placebo-Controlled Trial.
    The American journal of psychiatry, 2022, 12-01, Volume: 179, Issue:12

    Topics: Behavior Therapy; Binge-Eating Disorder; Bupropion; Double-Blind Method; Female; Humans; Male; Middl

2022
An open-label trial on the efficacy and tolerability of naltrexone/bupropion SR for treating altered eating behaviours and weight loss in binge eating disorder.
    Eating and weight disorders : EWD, 2021, Volume: 26, Issue:3

    Topics: Binge-Eating Disorder; Bupropion; Case-Control Studies; Feeding Behavior; Humans; Naltrexone; Weight

2021
A randomized, phase 3 trial of naltrexone SR/bupropion SR on weight and obesity-related risk factors (COR-II).
    Obesity (Silver Spring, Md.), 2013, Volume: 21, Issue:5

    Topics: Adult; Anti-Obesity Agents; Bupropion; Cardiovascular Diseases; Delayed-Action Preparations; Dopamin

2013
Bupropion for overweight women with binge-eating disorder: a randomized, double-blind, placebo-controlled trial.
    The Journal of clinical psychiatry, 2013, Volume: 74, Issue:4

    Topics: Adult; Body Mass Index; Bulimia; Bupropion; Dopamine Uptake Inhibitors; Double-Blind Method; Female;

2013
Effects of naltrexone sustained-release/bupropion sustained-release combination therapy on body weight and glycemic parameters in overweight and obese patients with type 2 diabetes.
    Diabetes care, 2013, Volume: 36, Issue:12

    Topics: Adolescent; Adult; Aged; Antidepressive Agents, Second-Generation; Blood Glucose; Body Weight; Bupro

2013
Patient-reported quality of life in a randomized placebo-controlled trial of naltrexone/bupropion for obesity.
    Clinical obesity, 2015, Volume: 5, Issue:5

    Topics: Adult; Aged; Anti-Obesity Agents; Bupropion; Drug Combinations; Female; Humans; Male; Middle Aged; N

2015
The relationship between early weight loss and weight loss at 1 year with naltrexone ER/bupropion ER combination therapy.
    International journal of obesity (2005), 2016, Volume: 40, Issue:9

    Topics: Adolescent; Adult; Anti-Obesity Agents; Bupropion; Drug Therapy, Combination; Female; Humans; Male;

2016
Naltrexone/Bupropion extended release-induced weight loss is independent of nausea in subjects without diabetes.
    Clinical obesity, 2016, Volume: 6, Issue:5

    Topics: Adult; Anti-Obesity Agents; Body Mass Index; Bupropion; Combined Modality Therapy; Delayed-Action Pr

2016
Method-of-use study of naltrexone sustained release (SR)/bupropion SR on body weight in individuals with obesity.
    Obesity (Silver Spring, Md.), 2017, Volume: 25, Issue:2

    Topics: Adolescent; Adult; Body Weight; Bupropion; Delayed-Action Preparations; Dopamine Uptake Inhibitors;

2017
Rational design of a combination medication for the treatment of obesity.
    Obesity (Silver Spring, Md.), 2009, Volume: 17, Issue:1

    Topics: Adult; Animal Feed; Animals; Antidepressive Agents; Bupropion; Disease Models, Animal; Drug Therapy,

2009
Comparison of combined bupropion and naltrexone therapy for obesity with monotherapy and placebo.
    The Journal of clinical endocrinology and metabolism, 2009, Volume: 94, Issue:12

    Topics: Adolescent; Adult; Appetite; Bupropion; Cohort Studies; Dopamine Uptake Inhibitors; Double-Blind Met

2009
Weight loss with naltrexone SR/bupropion SR combination therapy as an adjunct to behavior modification: the COR-BMOD trial.
    Obesity (Silver Spring, Md.), 2011, Volume: 19, Issue:1

    Topics: Adult; Antidepressive Agents; Behavior Therapy; Bupropion; Chemotherapy, Adjuvant; Combined Modality

2011
Weight loss with naltrexone SR/bupropion SR combination therapy as an adjunct to behavior modification: the COR-BMOD trial.
    Obesity (Silver Spring, Md.), 2011, Volume: 19, Issue:1

    Topics: Adult; Antidepressive Agents; Behavior Therapy; Bupropion; Chemotherapy, Adjuvant; Combined Modality

2011
Weight loss with naltrexone SR/bupropion SR combination therapy as an adjunct to behavior modification: the COR-BMOD trial.
    Obesity (Silver Spring, Md.), 2011, Volume: 19, Issue:1

    Topics: Adult; Antidepressive Agents; Behavior Therapy; Bupropion; Chemotherapy, Adjuvant; Combined Modality

2011
Weight loss with naltrexone SR/bupropion SR combination therapy as an adjunct to behavior modification: the COR-BMOD trial.
    Obesity (Silver Spring, Md.), 2011, Volume: 19, Issue:1

    Topics: Adult; Antidepressive Agents; Behavior Therapy; Bupropion; Chemotherapy, Adjuvant; Combined Modality

2011
Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
    Lancet (London, England), 2010, Aug-21, Volume: 376, Issue:9741

    Topics: Adult; Anti-Obesity Agents; Bupropion; Delayed-Action Preparations; Double-Blind Method; Drug Therap

2010
Bupropion versus sertraline in the treatment of depressive patients with binge eating disorder: retrospective cohort study.
    The Psychiatric quarterly, 2012, Volume: 83, Issue:2

    Topics: Adult; Antidepressive Agents; Binge-Eating Disorder; Body Mass Index; Bupropion; Depressive Disorder

2012
Bupropion SR vs. placebo for weight loss in obese patients with depressive symptoms.
    Obesity research, 2002, Volume: 10, Issue:10

    Topics: Adolescent; Adult; Aged; Blood Glucose; Blood Pressure; Bupropion; Cholesterol; Delayed-Action Prepa

2002
Bupropion treatment of olanzapine-associated weight gain: an open-label, prospective trial.
    Journal of clinical psychopharmacology, 2006, Volume: 26, Issue:4

    Topics: Adult; Aged; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Benzodiazepines; Buprop

2006
Combination therapy of zonisamide and bupropion for weight reduction in obese women: a preliminary, randomized, open-label study.
    The Journal of clinical psychiatry, 2007, Volume: 68, Issue:8

    Topics: Adult; Analysis of Variance; Anti-Obesity Agents; Bupropion; Drug Therapy, Combination; Female; Huma

2007
Bupropion for weight loss: an investigation of efficacy and tolerability in overweight and obese women.
    Obesity research, 2001, Volume: 9, Issue:9

    Topics: Adult; Anti-Obesity Agents; Bupropion; Dopamine Uptake Inhibitors; Double-Blind Method; Drug Adminis

2001
Bupropion SR enhances weight loss: a 48-week double-blind, placebo- controlled trial.
    Obesity research, 2002, Volume: 10, Issue:7

    Topics: Adolescent; Adult; Blood Glucose; Blood Pressure; Body Constitution; Bupropion; Cholesterol, HDL; De

2002

Other Studies

20 other studies available for bupropion and Weight Loss

ArticleYear
Circulating levels of proglucagon-derived peptides are differentially regulated by the glucagon-like peptide-1 agonist liraglutide and the centrally acting naltrexone/bupropion and can predict future weight loss and metabolic improvements: A 6-month long
    Diabetes, obesity & metabolism, 2023, Volume: 25, Issue:9

    Topics: Bupropion; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptide 2; Glucagon-Like Peptides; Human

2023
Naltrexone-bupropion for weight loss.
    Canadian family physician Medecin de famille canadien, 2023, Volume: 69, Issue:9

    Topics: Bupropion; Humans; Naltrexone; Weight Loss

2023
    Canadian family physician Medecin de famille canadien, 2023, Volume: 69, Issue:9

    Topics: Bupropion; Humans; Naltrexone; Weight Loss

2023
Weight-loss response to naltrexone/bupropion is modulated by the Taq1A genetic variant near DRD2 (rs1800497): A pilot study.
    Diabetes, obesity & metabolism, 2021, Volume: 23, Issue:3

    Topics: Bupropion; Genotype; Humans; Naltrexone; Pilot Projects; Polymorphism, Single Nucleotide; Protein Se

2021
[Pharmacotherapy for obesity].
    Nederlands tijdschrift voor geneeskunde, 2021, 01-19, Volume: 165

    Topics: Anti-Obesity Agents; Bariatric Surgery; Bupropion; Combined Modality Therapy; Drug Combinations; Dru

2021
Extended-release naltrexone/bupropion is safe and effective among subjects with type 2 diabetes already taking incretin agents: a post-hoc analysis of the LIGHT trial.
    International journal of obesity (2005), 2021, Volume: 45, Issue:8

    Topics: Aged; Anti-Obesity Agents; Body Weight; Bupropion; Diabetes Mellitus, Type 2; Female; Humans; Hypogl

2021
Early improvement in food cravings are associated with long-term weight loss success in a large clinical sample.
    International journal of obesity (2005), 2017, Volume: 41, Issue:8

    Topics: Adult; Bupropion; Clinical Trials, Phase III as Topic; Craving; Dopamine Uptake Inhibitors; Feeding

2017
Beyond lifestyle interventions: exploring the potential of anti-obesity medications in the UK.
    Clinical obesity, 2018, Volume: 8, Issue:3

    Topics: Anti-Obesity Agents; Bariatric Surgery; Body Weight Maintenance; Bupropion; Health Services; Humans;

2018
Combination therapy with naltrexone and bupropion for obesity reduces total and visceral adiposity.
    Diabetes, obesity & metabolism, 2013, Volume: 15, Issue:9

    Topics: Absorptiometry, Photon; Adiposity; Analysis of Variance; Body Composition; Bupropion; Dopamine Uptak

2013
Effect of combined naltrexone and bupropion therapy on the brain's reactivity to food cues.
    International journal of obesity (2005), 2014, Volume: 38, Issue:5

    Topics: Adolescent; Adult; Appetite; Bupropion; Cues; Diet; Dopamine Uptake Inhibitors; Drug Therapy, Combin

2014
Contrave--a combination of bupropion and naltrexone for weight loss.
    The Medical letter on drugs and therapeutics, 2014, Nov-10, Volume: 56, Issue:1455

    Topics: Anti-Obesity Agents; Bupropion; Drug Approval; Drug Combinations; Drug Interactions; Humans; Naltrex

2014
Lorcaserin, phentermine topiramate combination, and naltrexone bupropion combination for weight loss: the 15-min challenge to sort these agents out.
    International journal of clinical practice, 2014, Volume: 68, Issue:12

    Topics: Benzazepines; Bupropion; Drug Combinations; Drug Prescriptions; Fructose; Humans; Naltrexone; Obesit

2014
D1 and D2 antagonists reverse the effects of appetite suppressants on weight loss, food intake, locomotion, and rebalance spiking inhibition in the rat NAc shell.
    Journal of neurophysiology, 2015, Volume: 114, Issue:1

    Topics: Action Potentials; Animals; Appetite Depressants; Benzazepines; Bupropion; Diethylpropion; Dopamine

2015
Naltrexone + bupropion (Mysimba). Too risky for only modest weight loss.
    Prescrire international, 2015, Volume: 24, Issue:164

    Topics: Anti-Obesity Agents; Blood Pressure; Bupropion; Drug Combinations; Drug Interactions; Humans; Mental

2015
Answers to Clinical Questions in the Primary Care Management of People with Obesity: Pharmacologic Management.
    The Journal of family practice, 2016, Volume: 65, Issue:7 Suppl

    Topics: Anti-Obesity Agents; Benzazepines; Body Mass Index; Bupropion; Guidelines as Topic; Humans; Lactones

2016
Improving efficacy of the adjustable gastric band: studies of the use of adjuvant approaches in a rodent model.
    Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery, 2017, Volume: 13, Issue:2

    Topics: Adipose Tissue, Brown; Animals; Anti-Obesity Agents; Blood Glucose; Body Composition; Body Fat Distr

2017
Obesity Epidemic: Pharmaceutical Weight Loss.
    Rhode Island medical journal (2013), 2017, Mar-01, Volume: 100, Issue:2

    Topics: Anti-Obesity Agents; Benzazepines; Body Mass Index; Bupropion; Drug Combinations; Fructose; Humans;

2017
Miracle pills for weight loss: what is the number needed to treat, number needed to harm and likelihood to be helped or harmed for naltrexone-bupropion combination?
    International journal of clinical practice, 2010, Volume: 64, Issue:11

    Topics: Adolescent; Adult; Aged; Anti-Obesity Agents; Body Mass Index; Bupropion; Delayed-Action Preparation

2010
What cost weight loss?
    Circulation, 2012, Mar-06, Volume: 125, Issue:9

    Topics: Anti-Obesity Agents; Benzazepines; Bupropion; Cyclobutanes; Fructose; Humans; Naltrexone; Obesity; P

2012
Catecholamine reuptake inhibition causes weight loss by increasing locomotor activity and thermogenesis.
    Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2008, Volume: 33, Issue:6

    Topics: Animals; Area Under Curve; Behavior, Animal; Bupropion; Catecholamines; Dopamine Uptake Inhibitors;

2008